Mark Denison Archives

Resistance to COVID-19 drug detected in lab study

May. 10, 2022—Vanderbilt research shows that the virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.

Award winners and faculty pose for a photo before last week’s School of Medicine Spring Faculty Meeting.

Faculty awards honor teaching, clinical, research excellence

May. 5, 2022—The 2022 Vanderbilt University School of Medicine Academic Enterprise Awards for Excellence in Teaching, Extraordinary Performance of Clinical Service, and Outstanding Contributions to Research were presented April 29 during the annual spring faculty meeting.

VUMC faculty members attending the meeting of the American Society for Clinical Investigation included, from left, Wesley Ely, MD, MPH, Patrick Hu, MD, PhD, Lorraine Ware, MD, Kimryn Rathmell, MD, PhD, Consuelo Wilkins, MD, MSCI, Christopher Williams, MD, PhD, Lori Jordan, MD, PhD, Natasha Halasa, MD, MPH, ASCI Council Member Julie Bastarache, MD, Eric Tkaczyk, MD, PhD, and James Crowe Jr., MD.

VUMC a national leader in physician-scientist training

Apr. 21, 2022—Physician-scientists from Vanderbilt University Medical Center were well represented at the recent annual meeting of the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP) and the American Physician-Scientist Association.

VUMC researchers involved in developing Moderna’s COVID-19 vaccine featured in Smithsonian exhibit

Nov. 23, 2021—Researchers at Vanderbilt University Medical Center who contributed to the development of Moderna’s COVID-19 vaccine are featured in a new exhibit at the Smithsonian Institution in Washington, D.C.

Seven from VUMC among most highly cited researchers

Nov. 18, 2021—Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

VUMC research contributed to first COVID-19 pill now under review

Oct. 1, 2021—Vanderbilt research helped allow pharmaceutical giant Merck & Co. to authorization for the first oral antiviral pill to treat COVID-19.

COVID treatment studied by VUMC gains FDA approval

Oct. 26, 2020—Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.

VUMC studies provide key positive results for COVID-19 vaccine in early-stage clinical trial

Jul. 14, 2020—An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.

New study supports remdesivir as COVID-19 treatment

Jul. 9, 2020—This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.